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Belgrade, Serbia
cDepartment for Medical Biochemistry, Labo
Faculty of Pharmacy, University of Belgrade
dInstitute of Histology and Embryology, Fac
Serbia
eDepartment of Life Sciences and Chemistry,
Bremen, Germany. E-mail: u.kortz@jacobs-u
fCenter for Medical Biochemistry, Clinical C
gInstitute of Medical Chemistry, Faculty
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In this study, the in vivo hypoglycemic effect of a donut-shaped polyanion salt (NH4)14[Na@P5W30O110]$
31H2O {NaP5W30} and its Ag-containing derivative K14[Ag@P5W30O110]$22H2O$6KCl {AgP5W30}, as well
as their hepatotoxicity and nephrotoxicity, was evaluated. In the screening hypoglycemic study, Wistar
albino rats with streptozotocin induced diabetes were treated intraperitoneally with three single doses (5,
10, and 20 mg per kg per b.w.) of both investigated polyoxotungstates. The blood glucose levels,
measured before and after 2, 4 and 6 h polyoxotungstate application, showed that both studied
compounds induced the most pronounced and time dependent glucose lowering effects at the doses of
20 mg kg1. Thus, daily doses of 20 mg kg1 were administered to Wistar albino rats orally for 14 days in
further toxicity examinations. The serum glucose concentration and biochemical parameters of kidney
and liver function, as well as a histopathological analysis of kidney and liver tissues were evaluated 14
days after the polyoxotungstate administration. Both investigated compounds did not induce statistically
significant alterations of the serum glucose and uric acid concentrations, as well as some of the liver
function markers (serum alanine and aspartate aminotransferases, and alkaline phosphatase activities).
However, the significant decrease in serum total protein and albumin concentrations and the increase in
biochemical parameters of renal function – serum urea (up to 63.1%) and creatinine concentrations (up
to 23.3%) were observed for both polyoxotungstates. In addition, the detected biochemical changes
were in accordance with kidney and liver histhopathological analysis. Accordingly, the hepatotoxic and
nephrotoxic effects of these potential antidiabetic polyoxotungstates could be considered as mild.Introduction
Diabetes mellitus (DM) is the most common chronic metabolic
disease in humans. The hallmark of metabolic abnormality
associated with DM is the hyperglycemia either due to thelty of Medicine, University of Belgrade,
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55defective secretion of insulin or the insulin insensitivity or
both.1 DM is classied into two main types: type 1 or immune-
mediated diabetes (previously referred to as insulin-dependent
or juvenile-onset diabetes) and type 2 (previously called insulin-
independent or adult-onset diabetes). Immune-mediated dia-
betes represents approximately 5–10% of all cases of diabetes,
and is characterized by the autoimmune destruction of the
b cells in the endocrine pancreas, that usually results in the
absolute insulin deciency. On the other hand, type 2 accounts
for about 90–95% of all diabetes cases, in which there is
a progressive defect in insulin secretion on the background of
insulin resistance.2 Both forms of DM may lead to macro-
vascular (myocardial infarction, stroke and limb amputation)
and microvascular (retinopathy, nephropathy, and neuropathy)
complications, and early mortality.3 Lifestyle-directed inter-
ventions, insulin, sulfonylureas, metformin, dipeptidyl
peptidase-4 (DPP-4) inhibitors, sodium glucose transporter 2
inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonist
are used in the treatment of DM by decreasing the level of
glucose in the blood.4,5 The actual therapies are effective, butThis journal is © The Royal Society of Chemistry 2020
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View Article Onlineoen restricted because of their ways of application, side
effects, loss of the efficacy aer long-term use, cost and
unavailability in rural areas where they are mostly needed.6
Thus, the development of new potent and comfortable classes
of blood glucose-lowering medications with minimal side
effects to supplement actual therapeutics is urgently needed.
Accordingly, in vivo studies7–9 revealed that some poly-
oxometalates (POMs) induced normoglycemic effects in dia-
betic animal models. Therefore the investigation of POM
normoglycemic properties might be a promising research
direction resulting in the development of comfortable and low-
cost POM-based antidiabetic drugs.
POMs are discrete, negatively-charged metal-oxo clusters
comprising early d-block metal ions in high oxidation states
(e.g. W6+, V5+). Earlier studies showed that these inorganic drug
candidates possess potential anti-viral,10–12 -bacterial,13,14
-protozoal,15 -tumor,16,17 -Alzheimer18 and -diabetic activities.8,9
However, their molecular modes of action are poorly under-
stood. The approved selective and potent inhibition of enzymes
located on the cell surface, such as cholinesterases,19 phos-
phatases,15,20 ecto-nucleotidases21,22 and kinases,23 is supposed
to be a putative mechanism of the POM biological activities.
The aim of this study was to evaluate in vivo hypoglycemic
effects of the donut-shaped polyanion salt
(NH4)14[Na@P5W30O110]$31H2O {NaP5W30} and its Ag-
containing derivative K14[Ag@P5W30O110]$22H2O$6KCl
{AgP5W30} using Wistar albino rats with streptozotocin (STZ)-
induced diabetes as an experimental model. Furthermore, as
these POMs demonstrated promising hypoglycemic action,
their hepatotoxicity and nephrotoxicity were evaluated by
monitoring some biochemical and histopathological parame-
ters before further studies regarding mechanism of the antidi-
abetic action.
Material and methods
Chemicals
All reagents and chemicals employed for the POM synthesis
were of high-purity grade and used as purchased without
further purication. STZ was purchased from Sigma-Aldrich
(Munich, Germany).
Synthesis of polyoxotungstates
{NaP5W30} and {AgP5W30} were synthesized according to the
previously published procedures.24
Experimental animals
Male Wistar albino rats 6 weeks old and weighing 250–350 g
bred in the animal house of Military Medical Academy Research
Facility (Belgrade, Serbia) were used for this experiment. This
study was carried out in strict accordance with the Animal
Welfare Act of the Republic of Serbia (Official Gazette of the
Republic of Serbia no. 41/09), Directive 2010/63 EU on the
Protection of Animals Used for Scientic Purposes, and the
Guide for the Care and Use of Laboratory Animals (National
Research Council, 8th ed. Washington, USA). The methodologyThis journal is © The Royal Society of Chemistry 2020used in our investigation was approved by the Ethical
Commission for the Welfare Protection of Experimental
Animals (Faculty of Medicine, University of Belgrade, Serbia).
The animals were kept in the clean Plexiglas cages (48  37.5 
21 cm), and were maintained at the local animal house condi-
tions of temperature 23  2 C, humidity 65  5%, and 12 h
light/dark cycle with free access to food and water. Aer
randomization into various groups, the rats were acclimatized
to the laboratory conditions of temperature and photoperiod for
a period of 1–2 weeks before initiation of the experiments. The
weight of the rats was measured before the start of the experi-
ment, and was followed up each day through the course of the
experiment.
In vivo screening of hypoglycemic effect induced by
polyoxotungstates
Induction of diabetes. DM was induced by a single intra-
peritoneal injection of freshly prepared STZ, single dose of
50 mg per kg per body weight (b.w.).25 Diabetes in STZ-rats was
conrmed by measuring the fasting blood glucose level, 96 h
aer the STZ injection. Rats with blood glucose levels >12 mmol
L1 were considered as diabetic, and separated for the study.
The glucose levels from the tail-vein blood samples were fol-
lowed by GlucoSure Autocode Blood Glucose Monitoring
System (Houston, Texas, USA).
Experimental design. One week aer the diabetes induction,
when hyperglycemia was stabilized, the rats were divided into
different groups (n ¼ 5 per group). Three different single doses
(5, 10, and 20 mg per kg per b.w.) of the both investigated
polyoxotungstates were administered intraperitoneally (ip).
Blood glucose levels were determined before and aer 2, 4 and
6 h of polyoxotungstate application. The dose of 20 mg per kg
per b.w. showed maximum hypoglycemic effect, and thus was
selected for further toxicity examinations.
Toxicity evaluation of {NaP5W30} and {AgP5W30}
Experimental design. The rats were distributed into three
groups (n ¼ 7 per group):
 Control, 0.9% NaCl
 {NaP5W30}, 20 mg kg1
 {AgP5W30}, 20 mg kg1
The animals in the Control group received saline (0.9%
NaCl) per os for 14 days. The animals in the groups {NaP5W30}
and {AgP5W30} received the investigated POMs per os, in the
daily doses of 20mg per kg per b.w. for 14 days. All experimental
animals were followed for 14 days when the rats were sacriced,
and the blood samples were collected via cardiac puncture. The
kidney and liver samples of each animal were taken post mor-
tem, for a histological evaluation. Since the chosen poly-
oxotungstates had never been in vivo tested before, the selection
of exposure periods for monitoring of parameters was made
according to recommended protocol (OECD Guidelines for the
Testing of Chemicals, Acute Oral Toxicity – Fixed Dose
Procedure).
Determination of biochemical parameters. The samples of
collected blood were centrifuged, and biochemical markers ofRSC Adv., 2020, 10, 2846–2855 | 2847
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View Article Onlinekidney (serum concentrations of urea – SUr, creatinine – SCr and
uric acid – SUA) and liver function (serum activities of aspartate
aminotransferase – AST, alanine aminotransferase – ALT, and
alkaline phosphatase – ALP, as well as serum total protein – TP,
and albumin – Alb concentrations), and glucose concentrations
– SGl were determined in the serum samples spectrophotomet-
rically. The results were expressed as median (range). One Way
ANOVA followed by Tukey's Multiple Range Test (GraphPad
Prism 5, La Jolla California, USA) was used to determine the
statistical signicance of difference among the groups.
Histological evaluation
Tissues preparation. All tissue samples were xed in 4%
buffered formaldehyde for light microscopy, and in 3% glutar-
aldehyde for electron microscopy.
Light microscopy. The tissue samples xed in formaldehyde
were dehydrated and embedded in paraffin. 5 mm thick paraffin
sections were stained with Hematoxylin and Eosin (HE).
Micrographs were taken under the light microscope (Leica
DMLS, Hicksville, New York, USA) by a digital camera (Leica
DFC295, Hicksville, New York, USA).
Transmission electron microscopy. Tissue samples xed with
3% glutaraldehyde in cacodylate buffer were postxed in 1%OsO4.
Aer dehydration in graded alcohols, the cells were embedded in
Epoxy medium (Sigma-Aldrich, 45345). Thin sections were
mounted on copper grids (Sigma-Aldrich, G4901), and stained
with uranyl acetate and lead citrate for the examination on an
electron microscope (Morgagni 268D, FEI, Hillsboro, OR).
Results
Inuence of {NaP5W30} on the blood glucose levels in STZ-
induced diabetic rats
The blood glucose level measured in STZ-induced diabetic rats
before and aer 2, 4 and 6 h {NaP5W30} ip application in three
different single doses (5, 10, and 20 mg per kg per b.w.) areFig. 1 The effect of {NaP5W30} on the blood glucose level in STZ-diabetic
¼ 0 h) in three different single doses (5, 10, and 20 mg per kg per b.w.).
POM application. The values are expressed as mean  S.E.M. The re
significance. The blood glucose levels after 2 h, 4 h, and 6 h of {NaP5W30
corresponding pretreatment diabetic control values for all administrated
% of diabetic control) at three {NaP5W30} doses 6 hours after the treatm
2848 | RSC Adv., 2020, 10, 2846–2855expressed as mean  S.E.M (Fig. 1A). The repeated measures
ANOVA test (GraphPad Prism 5, La Jolla California, USA) was
used for the determination of the statistical signicance. A
time- (Fig. 1A) and dose- (Fig. 1B) dependent hypoglycemic
effect was observed. The investigated polyoxotungstate (5 mg
per kg per b.w) signicantly reduced (P < 0.05) the blood glucose
level (in mmol L1) aer 2 h, 4 h, and 6 h administration (22.94
 1.28, 21.51  1.31, and 20.30  0.86, respectively) compared
to the pretreatment diabetic control value (28.06  1.20).
Similarly, 10 mg per kg per b.w. of {NaP5W30} signicantly
reduced (P < 0.05) the blood glucose level 2 h aer the admin-
istration, and the hypoglycemic effect was sustained over a 2 to
6 hour period. 20 mg kg1 of {NaP5W30} showed the maximum
hypoglycemic effect. A signicant decrease (P < 0.05) in the
blood glucose level aer 2, 4 and 6 h application of the inves-
tigated compounds (24.22  1.16 mmol L1, 21.36 1.30 mmol
L1, and 18.40  1.02 mmol L1, respectively) in respect to the
pretreatment diabetic control value (29.62  1.24 mmol L1)
was obtained (Fig. 1A).
Inuence of {AgP5W30} on the blood glucose levels in STZ-
induced diabetic rats
The effect of {AgP5W30} on the blood glucose level in STZ-
induced diabetic rats aer 2, 4 and 6 h ip administration in
three different single doses (5, 10, and 20 mg per kg per b.w.)
was also examined. The results (expressed as mean  S.E.M)
showed that 5 mg per kg per b.w. and 10 mg per kg per b.w. of
{AgP5W30} did not have a signicant effect (P > 0.05) on the
blood glucose level in STZ-induced diabetic rats (Fig. 2). On the
other hand, 20 mg per kg per b.w of the investigated poly-
oxotungstate signicantly reduced (P < 0.05) the blood glucose
level (in mmol L1) from 24.08  4.41 to 21.54  4.36, 17.06 
3.74, and 14.60  3.54, 2 h, 4 h and 6 h, respectively, aer the
administration (Fig. 2). The repeated measures ANOVA test
(GraphPad Prism 5, La Jolla California, USA) determined the
statistical signicance of difference between the groups.rats. The investigated compound was administered intraperitoneally (t
(A) The blood glucose level was determined 2, 4, and 6 hours after the
peated measures ANOVA test was used to determine the statistical
} administration were significantly reduced (P < 0.05) in respect to the
doses (5, 10, and 20 mg kg1). (B) The blood glucose level (expressed as
ent.
This journal is © The Royal Society of Chemistry 2020
Fig. 2 The effect of {AgP5W30} on the blood glucose level in STZ-diabetic rats. The investigated polyoxotungstate was administered intra-
peritoneally (t ¼ 0 h) in three different single doses (5, 10, and 20 mg per kg per b.w.). The blood glucose level determined 2, 4, and 6 hours after
the POM application. The values are expressed as mean  S.E.M. The repeated measures ANOVA test was used to determine the statistical
significance of difference among groups.
Fig. 3 The effects of {NaP5W30} (20 mg per kg per day per os) and
{AgP5W30} (20 mg per kg per day per os) on serum glucose concen-
trations. In Control group, the rats received saline (0.9% NaCl) per os
for 14 days. Blood samples were taken after 14 days POM (or saline)
application. The results are presented as median (range) values. One
Way ANOWA followed by Tukey's Multiple Range Test was used to
determine the statistical significance of difference among groups.
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View Article OnlineToxicity evaluation of {NaP5W30} and {AgP5W30}
General habit of animals. The rats were observed twice daily
(morning and aernoon). Sleeping and feeding monitoring, as
well as the inspection of skin and visible mucosa was followed
through the whole experiment period according to ref. 26.
During the two-week follow-up, the rats did not show any
signicant differences in behaviour regarding sleeping and
feeding. Oral administration of POMs for two weeks did not
exert any effect on growth rate compared with untreated
animals. All changes in body weight were in line with the
timeframe of monitoring. Additionally, any changes in
appearances of the skin and mucosa of the animals were not
observed in the follow-up period.
Biochemical parameters. Fig. 3 shows the effect of
{NaP5W30} and {AgP5W30} on SGl in normal rats. The changes in
the serum glucose concentration were within the physiological
limits, and no a statistical difference (P > 0.05) was observed
between the untreated and treated animals.
To ascertain whether POMs induced renal damage, SUr, SCr
and SUA levels were measured in the rat serums. The effects of
both investigated compounds on these parameters are shown in
Fig. 4. The results demonstrated that {NaP5W30} and {AgP5W30}
induced statistically signicant increase of SUr level (in mmol
L1) [7.65 (7.13–8.87)] and [6.71 (6.30–7.07)] vs. [4.69 (4.05–5.76);
P < 0.001 and P < 0.05, respectively] (Fig. 4A), and SCr level
(in mmol L1) [40.7 (39.5–43.8)] and [39.5 (38.9–40.1)] vs. [33.00
(31.7–33.7); P < 0.001 and P < 0.001, respectively] (Fig. 4B)
compared with the Control group. On the contrary, SUA level was
within the physiological limits and no statistical difference (P >
0.05) was observed between the untreated and treated animals
(Fig. 4C).
The hepatotoxic effects of the studied POMs were evaluated
through the liver enzyme activity (AST, ALT, and ALP), as well asThis journal is © The Royal Society of Chemistry 2020TP and Alb concentration in the rat serums. Both investigated
compounds did not induce a statistically signicant difference
(P > 0.05) in AST, ALT, and ALP activities between the untreated
and treated rats (Fig. 5A–C). However, both {NaP5W30} and
{AgP5W30} induced statistically signicant decrease in TP
concentration (in g L1) [59.60 (57.30–61.40)] and [58.20 (57.20–
59.60)] vs. [68.90 (64.50–69.90); P < 0.001 and P < 0.001,
respectively], and Alb concentration (in g L1): [28.90 (28.30–
30.50)] and [28.90 (28.40–30.30)] vs. [35.10 (34.00–35.90); P <
0.001 and P < 0.001, respectively], compared with the Control
group (Fig. 5D and E).RSC Adv., 2020, 10, 2846–2855 | 2849
Fig. 4 The effects of {NaP5W30} (20 mg per kg per day per os) and {AgP5W30} (20 mg per kg per day per os) on renal function parameters (A, B
and C: serum urea, creatinine and uric acid concentration, respectively). In Control group, the rats received saline (0.9% NaCl) per os for 14 days.
Blood samples were taken after 14 days POM (or saline) application. The results are presented as median (range) values. One Way ANOVA
followed by Tukey's Multiple Range Test was used to determine the statistical significance of difference among groups.*P < 0.05; ***P < 0.001.
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View Article OnlineHistopathological evaluation of POM-induced renal toxicity
Light microscopy. The photomicrographs of the HE-stained
kidney tissues excised from the treated and untreated rats are
shown in Fig. 6. The sections obtained from the animals orallyFig. 5 The effects of {NaP5W30} (20 mg per kg per day per os) and {AgP5W
D and E: AST, ALT and ALP activities, and total protein and albumin con
saline (0.9% NaCl) per os for 14 days. Blood samples were taken after 14
(range) values. One Way ANOVA followed by Tukey's Multiple Range Test
groups. *P < 0.05; ***P < 0.001.
2850 | RSC Adv., 2020, 10, 2846–2855treated with both {NaP5W30} and {AgP5W30} (20 mg per kg per
day, 14 days) were similar to the normal rats; showing the
kidney section with normal histology of glomeruli, tubules,
interstitium and blood vessels.30} (20 mg per kg per day per os) on liver function parameters (A, B, C,
centrations in serum, respectively). In Control group, the rats received
days POM (or saline) application. The results are presented as median
was used to determine the statistical significance of difference among
This journal is © The Royal Society of Chemistry 2020
Fig. 6 Photomicrographs of HE-stained rat kidney sections. Tissues were stained with haematoxylin and eosin, and image was captured under
light microscope with 5 (a–c) and 40 (d–f) magnifications; (a and d) ¼ tissues from control rats treated with saline; (b and e) ¼ tissues from
rats treated with 20mg per kg per day {NaP5W30}; (c and f) are tissues from 20mg per kg per day {AgP5W30}-treated rats. No difference between
the kidney tissues from the treated and control rats.
Fig. 7 TEM micrographs presenting the ultrastructure of tubules in examined kidneys in untreated rat (a and d), in rat treated with 20 mg per kg
per day {NaP5W30} (b and e) and in rat treated with 20 mg per kg per day {AgP5W30} (c and f). Low power magnification (2800) of tubules:
unaltered tubules with prominent basal labyrinth in control rat (a), tubules with disorganized basal labyrinth and condensation of mitochondrial
matrix in {NaP5W30} (b) and {AgP5W30} (c) treated rats. High power magnification (14 000) of: the cytoplasm of epithelial cell in tubules with
unalteredmitochondria in kidney of control rat (d), cytoplasm of tubular epithelial cell in kidney tubules with electron densemitochondria (arrow)
in {NaP5W30} treated animal (e), and cytoplasm of epithelial cells of kidney tubules with distorted mitochondria (arrow) in {AgP5W30} treated
animal (f).
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View Article OnlineTransmission electron microscopy (TEM). The tubules in the
kidney samples obtained from the animals orally treated with
both {NaP5W30} and {AgP5W30} (20 mg per kg per day, 14 days)
altered the mitochondria that appeared dark and oedematous
(Fig. 7b and c), while the glomeruli were not altered.This journal is © The Royal Society of Chemistry 2020Histopathological evaluation of POM-induced liver toxicity
Light microscopy. The discrete elds of focal necrosis
between the lobules were observed in liver tissue samples ob-
tained from the animals orally treated with {NaP5W30} (20 mg
per kg per day, 14 days) (Fig. 8b and c). Additionally, liverRSC Adv., 2020, 10, 2846–2855 | 2851
Fig. 8 Photomicrographs of HE-stained rat liver sections. Tissues were stained with haematoxylin and eosin, and imagewas captured under light
microscope with 5 (a–c) and 40 (d–f) magnifications; (a and d) ¼ tissues from control rats treated with saline; (b and e) ¼ tissues from rats
treatedwith 20mg per kg per day {NaP5W30} showing: discrete fields of focal nescrosis between lobules (arrows); (c and f) are tissues from 20mg
per kg per day {AgP5W30}-treated rats showing: focal necrosis in periportal regions (arrows).
Fig. 9 TEMmicrographs presenting the ultrastructure of liver (3500) in untreated rat (a), in rat treated with 20mg per kg per day {NaP5W30} (b),
and in rat treated with 20 mg per kg per day {AgP5W30} (c). Ultrastructural features of unaltered hepatocytes in control rat (a). Liver tissue with
field of necrosis accompanied with extravasated erythrocytes in rat treated with {NaP5W30} (b). Small fields of coagulation necrosis in {AgP5W30}
treated rat (c).
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View Article Onlinesection from the {AgP5W30}-treated rats also showed focal
necrosis in periportal regions (Fig. 8e and f).
Transmission electron microscopy. The hepatocytes in the
liver samples obtained from the animals orally treated with
{NaP5W30} (20 mg per kg per day, 14 days) exhibited the peril-
obular discrete elds of the focal necrosis accompanied with
the extravasated erythrocytes (Fig. 9b). The liver samples of the
animals treated with {AgP5W30} had more extensive elds of the
focal necrosis (Fig. 9c).Discussion
In this study hypoglycemic potential of a donut-shaped poly-
oxotungstate {NaP5W30} and its Ag
+-containing derivative
{AgP5W30} was veried for the rst time usingWistar albino rats2852 | RSC Adv., 2020, 10, 2846–2855with STZ-induced diabetes as a model system. Both studied
compounds induced the most pronounced and time dependent
glucose lowering effects at doses of 20 mg kg1 resulting in the
similar decrease of the glucose level (approximately 40%
compared to the untreated rats, 6 h aer the application). The
obtained hypoglycemic effect of the investigated poly-
oxotungstates is in agreement with previously published in vivo
studies that reported effective hypoglycemic actions of various
types of polyoxotungstates on different diabetic animal
models.7–9 According to literature, a few putative mechanisms of
POM induced normoglycemic action were indicated: a-gluco-
sidase activity inhibition that consequently results in the
reduced absorption of intestinal carbohydrates,8 insulin
mimetic effects including glucose uptake stimulation and
lipolysis inhibition,27 prevention of STZ-induced apoptosis ofThis journal is © The Royal Society of Chemistry 2020
Table 1 The effect of the investigated POMs on the body weight
Time point (days)
Body weight in grams (mean  S.E.M)
Control (n ¼ 7) {NaP5W30} (n ¼ 7) {AgP5W30} (n ¼ 7)
0 258.00  16.85 254.50  16.47 255.40  5.10
2 268.10  16.81 270.60  17.80 256.40  6.02
4 281.20  16.92 282.10  18.22 259.89  6.58
6 280.60  14.64 281.00  16.25 254.40  6.82
8 272.60  12.97 286.00  14.37 257.20  6.83
10 290.60  17.51 290.60  17.51 290.61  17.51
12 293.20  16.77 300.40  15.66 297.90  6.65
14 290.10  13.31 301.77  16.11 296.10  9.93
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View Article Onlinepancreatic b-cells, and stimulation of insulin synthesis.7 More-
over, some polyoxotungstates were found to prevent the devel-
opment of diabetic life-threatening microvascular and
macrovascular complications by signicant limitation of aldose
reductase activities and accumulation of advanced glycation
end products.8
The preference in the investigation of agents as potential
drugs for the treatment of different disorders is the assessment
of their safety. Although the evidence about the biological
activity of some POMs was reported for the rst time almost y
years ago, there is a relative lack of relevant data related to toxic
properties of POMs. Therefore, the present study was designed
to examine the in vivo nephrotoxic and hepatotoxic effects of
two structurally similar polyoxotungstates with above described
hypoglycemic activity.
The results of the acute 14 day oral toxicity study of the
investigated polyoxotungstates showed no adverse effects on
the animal behaviour regarding sleeping and feeding. Statisti-
cally signicant differences in food and water intake and body
mass between the treated and control rats were not observed.
Since changes in body mass is a sensitive marker of the general
health of the animals,28 it could be concluded that both
{NaP5W30} and {AgP5W30} in the oral dose of 20 mg per kg per
day did not induce severe toxic effects in the rats during the two-
week follow-up period of the experiment (Table 1). These nd-
ings are in agreement with previously published similar effects
obtained for the animals (rats and mice) treated with various
other polyoxotungstates.7,9,19
In addition, both studied polyoxotungstates (20 mg per kg
per day, 14 days) did not affect the serum glucose concentration
in the healthy rats (Fig. 3). Accordingly, our ndings and the
results of ref. 9 and 8 suggested that polyoxotungstates
administration within the dose tested in these studies may not
lead to hypoglycemia, which has been recognized as a side effect
of some currently available antidiabetic agents.29
During the development of a new drug, it is necessary to
examine the nephrotoxic properties of potential pharmaceutical
agents, because the kidney constitutes the major excretory
organ for most substances. Thus, the combination of functional
and histological parameters was evaluated for the purpose of
detecting nephrotoxic properties of the studied POMs. The
results of renal functional parameters (Fig. 4) showed that theThis journal is © The Royal Society of Chemistry 2020administration of both investigated POMs (20 mg per kg per
day, 14 days) induced statistically signicant increase of SUr and
SCr levels. On the other hand, SUA level was within the physio-
logical limits and no statistical difference was observed between
the untreated and treated animals. These nephrotoxic effects
were conrmed by TEM morphological studies of excised
kidneys that also showed mild renal damage (Fig. 7), although
light microscopy did not indicate differences between samples
taken from the POM treated and control rats (Fig. 6). The
morphological studies by TEM (Fig. 7) showed dark and
oedematous mitochondria in tubules of kidney samples ob-
tained from animals treated with both investigated compounds.
These nephrotoxic ndings for the polyoxotungstates could be
explained by the reported highest accumulation of the anti-viral
polyoxotungstate in the kidneys aer the oral application,30 but
mechanisms of POM-induced renal toxicity are still unknown.
In addition, the morphological changes of mitochondria indi-
cated that the one of putative nephrotoxic mechanisms of POMs
is oxidative stress increase in the kidney.
The biochemical and histopathological analysis were per-
formed to evaluate the possible alterations in liver function and
morphology induced by {NaP5W30} and {AgP5W30}. The results
of liver function indicators demonstrated that the administra-
tion of the investigated clusters did not induce statistically
signicant changes in serum AST, ALT, and ALP activities
(Fig. 5A–C). On the contrary, a statistically signicant decrease
in serum concentration of TP and Alb was detected for both
polyoxotungstates (Fig. 5D and E). The aminotransferase activ-
ities in serum are elevated with acute hepatic cell injury, while
elevated serum ALP activities are associated with cholestasis.31
Besides, TP and Alb concentrations are monitored in basic liver
function tests as the indicators of hepatic synthetic function.
Accordingly, the obtained results of hepatotoxicity evaluation
indicated that both investigated compounds (20 mg per kg per
day, 14 days) induced neither massive necrosis of hepatocytes
nor cholestasis; however, synthetic dysfunction of liver was
detected aer both POMs administration. Moreover, the results
of the biochemical analysis were conrmed by histological
examination of excised liver from the POM-treated and the
control rats. The results of histological analysis (Fig. 8 and 9)
revealed discrete elds of focal necrosis between lobules
accompanied with extravasated erythrocytes in {NaP5W30}-RSC Adv., 2020, 10, 2846–2855 | 2853
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View Article Onlinetreated rats, while {AgP5W30} induced more extensive elds of
focal necrosis in periportal regions. According to these results,
both investigated POMs with potential antidiabetic properties
only affected synthetic function of liver without massive and
severe damage in the applied dose.
Conclusions
It could be concluded that both investigated polyoxotungstates
demonstrated similar hypoglycemic effects in rats with STZ-
induced diabetes. Additionally, hepatotoxic and nephrotoxic
effects induced by 2 week POM treatments could be considered
as mild. The obtained results imply it is noteworthy to carry out
further studies, involving a mode of action as well as detailed
toxicological examinations, on these POM-based potential
antidiabetic agents. Moreover, this study presents a good plat-
form for design of novel low-cost inorganic antidiabetics with
more advanced characteristics.
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